GlobeNewsWire
20 Jan 2026, 19:13 UTC · 35w ago
Verdict
Headline takes no side. We score RAPT +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
GSK has entered into a definitive agreement to acquire RAPT Therapeutics for $2.2 billion.
More positive than 99% of claims this week
RAPT's lead candidate, ozureprubart, is in late-stage clinical development with a Phase 3 trial for chronic spontaneous urticaria expected in 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 78% of claims this week
The acquisition represents the second exit for Forbion Growth Fund III, following a $920 million exit of Astria Therapeutics in October 2025.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Company is being acquired in a transaction valued at $2.2 billion.
More positive than 75% of ticker scores this week
Acquiring a high-potential therapeutic candidate to expand its portfolio in severe allergic diseases.
More positive than 65% of ticker scores this week
Mentioned as having successfully acquired Astria Therapeutics for $920 million.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
10h ago
+65.3%
Price agrees with the score
$58.01 vs $35.10 close before publication (Jan 16) · not market-adjusted
RAPT chart →
